---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-26-000027"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T18:32:20.569511+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed

## Summary
- Revenue rose 12% YoY to $17.3M; net loss widened to $4.0M from $3.8M.
- AVISE CTD test volume increased 10% YoY; TTM ASP rose 6% to $444.
- Adjusted EBITDA loss improved 14% to $2.2M; cash $21.5M, ahead of expectations.
- Full-year 2026 revenue guidance reaffirmed at $70M-$73M.

## SEC filing metadata
- accession: 0001274737-26-000027
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473726000027/0001274737-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473726000027/exdx-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-26-000027
- JSON: https://secwatch.observer/filing/0001274737-26-000027.json
- Plain text: https://secwatch.observer/filing/0001274737-26-000027.txt

## Source-grounded claims
- claim_id: 377d84364689036ff7aaf4749223307abb0f945a
  claim: EXAGEN INC. reported the three months ended March 31, 2026 results: revenue $17.3 million, net income Net loss $ (3,967). Guidance reaffirmed.
  evidence_excerpt: Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473726000027/0001274737-26-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.